HL40626S

HL40626S is an oral small molecule inhibitor of Tyrosine Kinase 2 (TYK2) developed by Highslab Therapeutics. It is designed to treat autoimmune and inflammatory conditions, with a primary focus on psoriasis. TYK2 is a member of the Janus kinase (JAK) family that mediates signaling for key pro-inflammatory cytokines, including interleukin-23 (IL-23), IL-12, and Type I interferons. By targeting the TYK2 pathway, HL40626S aims to modulate the immune response involved in plaque psoriasis while potentially minimizing the off-target effects associated with broader JAK1/2/3 inhibition. The drug is currently undergoing Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy participants.